FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Immunotherapy topics
Immunotherapy
Therapeutics
Antibodies
Immune Response
Monoclonal
Monoclonal Antibody
Stimulator
Immunostimulator
Compatibility
Histocompatibility
Specificity
Major Histocompatibility Complex
Radiation Therapy
Treatments
Amino Acid

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Immunotherapy patents



      
           
This page is updated frequently with new Immunotherapy-related patent applications. Subscribe to the Immunotherapy RSS feed to automatically get the update: related Immunotherapy RSS feeds. RSS updates for this page: Immunotherapy RSS RSS


Date/App# patent app List of recent Immunotherapy-related patents
10/23/14
20140314795
 Method and compositions for cellular immunotherapy patent thumbnailMethod and compositions for cellular immunotherapy
The present invention provides methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring genetically modified tumor specific cd8+ t cells in the presence of tumor-specific, subset specific genetically modified cd4+ t cells, wherein the cd4+ t cells confer and/or augment a cd8+ t cells ability to sustain anti-tumor reactivity and increase and/or maximize tumor-specific proliferation of the tumor-specific cd8+ t cells of interest. Pharmaceutical formulations produced by the method, and methods of using the same, are also described..
10/16/14
20140308344
 Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation patent thumbnailMethods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient.
10/16/14
20140308305
 Yeast-based vaccines as immunotherapy patent thumbnailYeast-based vaccines as immunotherapy
Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle and an antigen that is selected to elicit an antigen-specific cellular and humoral immune response in an animal, for use in prophylactic and/or therapeutic vaccination and the prevention and/or treatment of a variety of diseases and conditions are disclosed..
10/16/14
20140308299
 Combination immunotherapy for the treatment of cancer patent thumbnailCombination immunotherapy for the treatment of cancer
Agonists to icos in combination with a blocking agent to a t cell inhibitory receptor (e.g., ctla-4, pd-1, etc.) are demonstrated herein to be useful for the treatment of tumors.. .
10/09/14
20140302098
 Yeast-based vaccines as immunotherapy patent thumbnailYeast-based vaccines as immunotherapy
Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle and an antigen that is selected to elicit an antigen-specific cellular and humoral immune response in an animal, for use in prophylactic and/or therapeutic vaccination and the prevention and/or treatment of a variety of diseases and conditions are disclosed..
10/09/14
20140301945
 Human anti-sod1 antibodies patent thumbnailHuman anti-sod1 antibodies
Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or sod1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for sod1 are also disclosed.
10/02/14
20140296480
 Peptide secreted by lactobacillus plantarum with immunomodulating function patent thumbnailPeptide secreted by lactobacillus plantarum with immunomodulating function
To summarize, the st peptide is considered to promote the process of immunologic ignorance of our gastrointestinal immune system toward the commensal bacteria of our gastrointestinal tract, thus favoring the mechanisms of oral tolerance. Therefore the st peptide could be used in immunotherapy, especially in the context of certain autoimmune diseases and certain inflammatory diseases..
10/02/14
20140294852
 Monoclonal antibodies to programmed death 1 (pd-1) patent thumbnailMonoclonal antibodies to programmed death 1 (pd-1)
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
10/02/14
20140294765
 Lsr antibodies, and uses thereof for treatment of cancer patent thumbnailLsr antibodies, and uses thereof for treatment of cancer
This invention relates to antibodies and antigen binding fragments and conjugates containing same, and/or alternative scaffolds, specific for lsr molecules, which are suitable drugs for immunotherapy and treatment of specific cancer.. .
09/25/14
20140286974
 Chimeric molecule useful in immunotherapy for leishmaniasis, which includes a fragment of the pfr1 protein of leishmania infantum with specific immunodominant epitopes patent thumbnailChimeric molecule useful in immunotherapy for leishmaniasis, which includes a fragment of the pfr1 protein of leishmania infantum with specific immunodominant epitopes
The present invention claims an isolated nucleotide sequence characterized by encoding the pfr1 protein of leishmania infantum or a fragment thereof. This pfr1 protein or a fragment thereof comprises at least a selected immunodominant epitope between the following group: seq id no: 1, seq id no: 2, seq id no: 3, seq id no: 4, seq id no: 5, seq id no: 6, seq id no: 7 and seq id no: 8, where the immunodominant epitope is able to induce an antigen-specific t cell cytotoxic immune response in an animal, against the kinetoplastids causing the leishmaniasis disease.
09/25/14
20140286963
Methods and compositions for neural disease immunotherapy
The invention provides antibodies to specific neural proteins and methods of using the same.. .
09/18/14
20140275495
Humanized antibodies that recognize alpha-synuclein
The present application discloses humanized 9e4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of lewy body disease..
09/18/14
20140271836
Manufacture of peanut formulations for oral desensitization
The present application relates to a method for managing the development and manufacturing process of a therapeutically effective formulation. Peanut proteins are characterized from peanut flour and encapsulated formulations made using the peanut flour for oral immunotherapy of peanut allergies..
09/18/14
20140271721
Peanut formulations and uses thereof
The present application relates to compositions for oral immunotherapy of peanut allergies. Further, the present application relates to methods for the preparation of the compositions for immunotherapy, and their use in immunotherapy..
09/18/14
20140271692
Novel immunogenic epitopes for immunotherapy
The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
09/18/14
20140271690
Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type
The present disclosure is directed to individual aβ peptide immunogen constructs, peptide compositions comprising these aβ peptide immunogen constructs and mixtures thereof, pharmaceutical compositions including vaccine formulations comprising these aβ peptide immunogen constructs, with the individual aβ peptide immunogen constructs having the n-terminus of the aβ peptide as the b cell (b) epitopes linked through spacer residue(s) to heterologous t helper cell (th) epitopes derived from pathogen proteins that act together to stimulate the generation of highly specific antibodies directed against the n-terminus of the aβ peptide offering protective immune responses to patients at risk for, or with, alzheimer's disease.. .
09/18/14
20140271638
Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas
Methods of treating, preventing or managing mantle cell lymphomas are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as revlimid® or lenalidomide.
09/18/14
20140271582
Cd123-specific chimeric antigen receptor redirected t cells and methods of their use
A family of chimeric antigen receptors (cars) containing a cd123 specific scfv was developed to target different epitopes on cd123. In some embodiments, such a cd123 chimeric antigen receptor (cd123car) gene includes an anti-cd123 scfv region fused in frame to a modified igg4 hinge region comprising an s228p substitution, an l235e substitution, and optionally an n297q substitution; a costimulatory signaling domain; and a t cell receptor (tcr) zeta chain signaling domain.
09/18/14
20140271477
Monoclonal antibodies to egfr, and uses therefor
The present invention relates to isolated monoclonal anti-egfr antibodies, and to the use of such antibodies and antibody fragments to detect egfr, particularly those expressed by cancer cells. The antibodies are useful in diagnostic as well as therapeutic indications.
09/11/14
20140256648
Hjurp peptides and vaccines including the same
Isolated peptides derived from seq id no: 50 and fragments thereof that bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) and thus are suitable for use in cancer immunotherapy are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, provided they retain the requisite cytotoxic t cell inducibility of the original sequence.
09/11/14
20140255437
Topk peptides and vaccines including the same
The present invention provides isolated epitope peptides derived from topk and immunogenic fragments thereof have an ability to induce cytotoxic t lymphocytes (ctls) and thus are suitable for use in cancer immunotherapy, more particularly as cancer vaccines. The peptides of the present invention encompass both of peptides including a topk-derived amino acid sequence and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted and/or added, provided such modified versions have ctl inducibility.
09/11/14
20140255434
Phl p 5a derivatives having reduced allergeneity and retained t-cell reactivity
The present invention relates to the preparation and use of variants of the group 5 allergen of the pooideae which are characterised by reduced ige reactivity compared with the known wild-type allergens and at the same time by substantially retained reactivity with t lymphocytes. These hypoallergenic allergen variants can be employed for the specific immunotherapy (hyposensitisation) of patients having grass pollen allergy or for the preventative immunotherapy of grass pollen allergies..
09/11/14
20140255433
Pde5 inhibitor compositions and methods for immunotherapy
The invention features methods and compositions featuring a pde5 inhibitor for treating or preventing immunological-mediated disease in a subject.. .
09/11/14
20140255411
Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against vsig1, ildr1, loc253012, ai216611, c1orf32 or fxyd3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages.
09/11/14
20140255389
Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against vsig1, ildr1, loc253012, ai216611, c1orf32 or fxyd3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages.
09/11/14
20140255304
Tdp-43 specific binding molecules
Provided are novel tdp-43-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these tdp-43 specific binding molecules.
09/04/14
20140248640
Methods for testing an immune response using cultures of t cells, b cells, dendritic cells and follicular dendritic cells
The present invention relates to methods for preparing an artificial immune system. The artificial immune system comprises a cell culture comprising t cells, b cells and antigen-primed dendritic cells.
09/04/14
20140248297
Predictors of response to immunotherapy
The invention is directed to a method to predict individuals who are likely to respond to immunotherapy by detecting enhanced levels of antibodies in the plasma or serum wherein the antibodies are characteristic of the response or non-response of pretested populations of subjects.. .
09/04/14
20140248283
Monoclonal antibodies against her2 antigens, and uses therefor
The present invention provides and includes monoclonal antibodies (mabs) preferentially selective for her2 antigens, hybridoma lines that secrete these her2 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect her2 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble or secreted form of her2.
08/28/14
20140242101
Pd-l1 based immunotherapy
The present invention relates to the field of prophylaxis and therapy of clinical conditions including cancer, autoimmune diseases and infectious diseases. In particular there is provided vaccine compositions comprising pd-l1 or peptide fragments thereof that are capable of eliciting immune responses useful in treatment of cancer, autoimmune diseases or infectious diseases..
08/28/14
20140242049
Mutant ctla4 gene transfected t cell and composition including same for anticancer immunotherapy
A transformed t-cell for t-cell therapy, and a composition including the same for anticancer immunotherapy. More particularly, the transformed t-cell is characterized by the transfection of a gene for coding a chimera protein.
08/21/14
20140234347
Methods of using biomarkers for predicting the outcome of an immunotherapy against cancer
The present invention relates to methods for predicting the effect of an immunotherapy against cancer in a patient based on new biomarkers. The present invention furthermore relates to a prognosis regarding the outcome based on said biomarkers.
08/07/14
20140220605
Vmp-like sequences of pathogenic borrelia species and strains
The present invention relates to dna sequences encoding vmp-like polypeptides of pathogenic borrelia, the use of the dna sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the dna and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, dna segments and antibodies..
08/07/14
20140220562
Method of predicting responsiveness of b cell lineage malignancies to active immunotherapy
Predictive biomarkers identify those patients suffering from immunoglobulin positive (ig+) b lineage malignancies that are responsive to active immunotherapy, where the active immunotherapy comprises vaccination with a tumor-specific idiotype-immunogen. It is shown herein that patient responsiveness to the idiotype-immunogen is dependent upon the sequence of the immunogen, where an immunogen having a low number of tyrosine residues in the cdr1 (herein termed cdr1-y10) regions of one or both of the immunogen heavy and light chains is predictive of a positive anti-tumor response, while a high number of cdr1 tyrosine residues (herein termed cdr1-yhi) is predictive of a low anti tumor response..
08/07/14
20140220011
Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against vsig1, ildr1, loc253012, ai216611, clorf32 or fxyd3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages.
08/07/14
20140219914
Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
07/31/14
20140212422
Methods for treating cancer using anti-pd-1 antibodies in combination with anti-ctla-4 antibodies
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
07/24/14
20140206724
Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient.
07/24/14
20140206723
Methods for treating amyloidosis with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient.
07/24/14
20140206654
Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of hematological dyscrasias and cancer of an organ
The present invention refers to the use of a compound of formula (i′) or pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of hematological dyscrasias, including myelodysplastic syndromes (mdss) and for improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy. In addition, it relates to the use of a compound of formula (i″) for the treatment and/or prophylaxis of cancer of an organ..
07/24/14
20140205680
Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
Methods of treating, preventing or managing cancer, including certain leukemias are disclosed. The methods encompass the administration of enantiomerically pure (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid.
07/17/14
20140199344
Anti-measles cancer immunotherapy
The present invention provides methods for treating specific populations of cancer patients by immunotherapy. The methods comprise administering an immunogenic composition eliciting an immune response to measles virus to patients having measles virus-immunoreactive cancer cells..
07/17/14
20140199336
Tmem22 peptides and vaccines including the same
Isolated peptides composed of the amino acid sequence of seq id no: 33 or fragments thereof that bind to hla antigens and have cytotoxic t lymphocyte (ctl) inducibility and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic t cell inducibility.
07/17/14
20140199298
Combination treatment of cancer comprising egfr/her2 inhibitors
Optionally in combination with radiotherapy, radio-immunotherapy and/or tumour resection by surgery, furthermore, the invention relates to corresponding medicaments and the preparation thereof.. .
07/10/14
20140193444
Allergen peptide fragments and use thereof for treatment of dust mite allergies
The present invention relates generally to in vivo methods and compositions designed for allergen specific immunotherapy. The compositions include contiguous overlapping peptide fragments which together form an entire amino acid sequence of an allergen..
07/10/14
20140193417
Membrane transporter napi2b (scl34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy
The present disclosure relates generally to the membrane transporter napi2b (slc34a2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The slc34a2 epitope peptide encompassing amino acids 312-340 of slc34a2 has been identified as an ovarian cancer epitope using the monoclonal antibody mx35.
07/03/14
20140186404
Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione in combination with antibodies
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient.
07/03/14
20140186401
Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy
In one embodiment, a single modality cancer immunotherapy regimen that includes a therapeutic composition is provided. Such a therapeutic composition may include a salmonella strain comprising a plasmid that expresses an shrna molecule that suppresses the expression of an immunosuppressive target and suppresses tumor growth.
07/03/14
20140186380
Immunotherapy with binding agents
Binding agents that modulate the immune response are disclosed. The binding agents may include soluble receptors, polypeptides, and/or antibodies.
07/03/14
20140186374
Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists
We demonstrate herein that neuritin controls the homeostasis of regulatory t cells in an antigen dependent manner. Based on this discovery, we describe herein the application of neuritin as a therapeutic agent to manipulate antigen specific regulatory t cells in various disease settings is described.
06/26/14
20140179004
Cell for use in immunotherapy which contains modified nucleic acid construct encoding wilms tumor gene product or fragment thereof, method for producing said cell, and said nucleic acid construct
A cell of the present invention contains a nucleic acid construct encoding a wt1 gene product or a fragment of the wt1 gene product. The nucleic acid construct contains (i) a region encoding a desired fragment of the wt1 gene product and (ii) only aug as a functional start codon.
06/26/14
20140178968
Genetic variant of cytomegalovirus (cmv)
The present invention relates to a genetic variant of cmv, said genetic variant lacking intron 2 of the ie region of cmv (cmv ieΔi2) the present invention also relates to various uses of this genetic variant as well as rna splice variants transcribed therefrom, and proteins expressed from the rna splice variants, such as in the diagnosis of a cmv related cancer disease, and identification of individuals at risk of developing cancer or risk of transferring the cmv ieΔi2 virus with a human sample and prevention and treatment through targeting of unique cmv ie proteins for immunotherapy and vaccination.. .
06/26/14
20140178906
Monoclonal antibodies against pcbp-1 antigens, and uses therefor
The present invention provides and includes monoclonal antibodies specific or preferentially selective for pcbp-1 antigens, hybridoma lines that secrete these pcbp-1 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect pcbp-1 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble form of pcbp-1.
06/26/14
20140178438
Individualized vaccines for cancer
The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a).
06/26/14
20140178409
Sema5b peptides and vaccines including the same
As discussed in detail herein, isolated epitope peptides derived from sema5b bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite hla binding and/or ctl inducibility of the original sequences.
06/26/14
20140178334
Methods and compositions for liquidation of tumors
This invention relates to compositions and methods for immunotherapy of cancer. Specifically, a method of cancer immunotherapy is described which results in the systemic liquidation of both solid and metastatic tumors whereever they reside in the body.
06/19/14
20140170225
Immunotherapy for treatment of amyloid-related disorders using encapsulated beta-amyloid peptides
The present invention relates to the field of polymer chemistry and more particularly to encapsulated peptides and uses thereof.. .
06/19/14
20140170063
Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 rop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
06/12/14
20140161806
Immunogenic synthetic glycoconjugate for the immunotherapy of melanoma
Wherein x is o, nh, s, ch2; l is a linker that is a divalent spacer; a is an adjuvant or carrier that is an immunogenic molecule or an immunogenic particle; and wherein bonds between linker and saccharide moiety and between linker and carrier are of covalent type; wherein the linker l presents a chemical structure suitable to space the saccharide moiety and the carrier by 7-30 atoms when the adjuvant/carrier a is a biomacromolecule or by 19-30 atoms when the adjuvant/carrier a is a metallic nanoparticle; wherein the carrier/adjuvant a can be selected among a macromolecule, a macrocycle, a dendrimer, a liposome, a nanoparticle, an oligosaccharide featuring from two to five monosaccharidic units or cells like dendritic cells.. .
06/12/14
20140161773
Use of an agent that restores tissue perfusion and oxygenation
The presently disclosed subject matter provides methods for increasing perfusion in hypoxic regions of tissues in subjects. Also provided are methods for treating diseases and/or disorders associated with hypoxia in subjects, methods for increasing sensitivity of tumors to radiation and/or chemotherapy treatments, methods for delaying tumor growth in subjects, and methods for inhibiting tumor blood vessel growth in subjects.


Popular terms: [SEARCH]

Immunotherapy topics: Immunotherapy, Therapeutics, Antibodies, Immune Response, Monoclonal, Monoclonal Antibody, Stimulator, Immunostimulator, Compatibility, Histocompatibility, Specificity, Major Histocompatibility Complex, Radiation Therapy, Treatments, Amino Acid

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Immunotherapy for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunotherapy with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



1.0106

3539

70 - 0 - 71